NCT03478566View on ClinicalTrials.gov

Transcutaneous CO2 Monitoring at Home for Children With Neuromuscular Disease

NAActive, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

September 1, 2023

Conditions
Sleep Disorder; Breathing-RelatedCentral ApneaNeuromuscular DiseasesObstructive Sleep Apnea
Interventions
DEVICE

Transcutaneous CO2 monitoring

The aim is to assess the accuracy of ambulatory, at home, transcutaneous CO2 monitoring in pediatric Neuromuscular Disease (NMD).

Trial Locations (1)

M5G 1X8

The Hospital for Sick Children, Toronto

All Listed Sponsors
lead

The Hospital for Sick Children

OTHER

NCT03478566 - Transcutaneous CO2 Monitoring at Home for Children With Neuromuscular Disease | Biotech Hunter | Biotech Hunter